Prolonged shedding of infectious viruses with haplotype switches of SARS-CoV-2 in an immunocompromised patient.
COVID-19
Haplotype
Immunocompromised host
Infectivity
Viral kinetic
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
03
01
2022
revised:
20
03
2022
accepted:
03
04
2022
pubmed:
18
4
2022
medline:
14
5
2022
entrez:
17
4
2022
Statut:
ppublish
Résumé
A concern has been raised that the persistent COVID-19 infection in an immunocompromised host can be the source of the SARS-CoV-2 variants. This is the case of a 61-year-old man in complete remission of a follicular lymphoma after six cycles of rituximab and bendamustine with additional two cycles of rituximab completed eight months prior to the episode of COVID-19 pneumonia. The patient's respiratory failure was long-lasting, and required mechanical ventilation until day 75. Acquired immunity tested negative throughout the observational period. The viral RNA was detectable until day 100 while the infectious virus was isolated until day 79. Seven haplotypes were identified and the non-synonymous mutations accumulated in the spike gene which included E484Q and S494P. In the management of COVID-19 cases with suppressed immune statuses, initial evaluation of existing immunity and monitoring for infectiousness throughout the clinical course including the convalescent stage may be necessary.
Identifiants
pubmed: 35430092
pii: S1341-321X(22)00113-1
doi: 10.1016/j.jiac.2022.04.004
pmc: PMC8986523
pii:
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1001-1004Informations de copyright
Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Immunotherapy. 2018 Jun;10(8):713-728
pubmed: 29569510
Virus Res. 2020 Oct 2;287:198098
pubmed: 32687861
Clin Infect Dis. 2022 Jan 29;74(2):237-245
pubmed: 33906227
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Sci Rep. 2016 Mar 14;6:23002
pubmed: 26972611
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
J Med Virol. 2022 Mar;94(3):1035-1049
pubmed: 34676891
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
Nat Commun. 2022 Mar 17;13(1):1547
pubmed: 35301314
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Nature. 2020 May;581(7807):215-220
pubmed: 32225176